VEP and PERG in patients with multiple sclerosis, with and without a history of optic neuritis
Tóm tắt
Visual electrophysiology is routinely used to detect the visual complications of multiple sclerosis, but the analysis mostly focuses on visual evoked potential (VEP) and especially the P100 component. Our goal was to analyze the components and waveform alterations of VEPs and pattern electroretinograms (PERGs) in patients with multiple sclerosis (MS) with good vision. The main VEP and PERG components of 85 patients with MS were analyzed in two groups: 38 patients who had optic neuritis in their history (ON group) and 47 patients who had never had optic neuritis (MS group). The results were compared against a control group of 47 healthy subjects. Both VEP and PERG alterations occurred in a greater number of patients than expected, and these alterations were not necessarily linked to ON in the history or a deterioration of visual acuity. Both VEP and PERG can detect dysfunction in the visual system in MS, even if the patient has no subjective symptoms. Even if PERG is not routinely used in neuro-ophthalmology, the results suggest that PERG assessment may provide useful information describing the retinal defect in MS.
Tài liệu tham khảo
Halliday AM, McDonald WI, Mushin J (1973) Visual evoked response in diagnosis of multiple sclerosis. Br Med J 4(5893):661–664
Odom JV, Bach M, Brigell M, Holder GE, McCulloch DL, Mizota A et al (2016) ISCEV standard for clinical visual evoked potentials: (2016 update). Doc Ophthalmol 133(1):1–9
Sand T, White LR, Hagen K, Stovner LJ (2009) Visual evoked potential and spatial frequency in migraine: a longitudinal study. Acta Neurol Scand Suppl 189:33–37
Di Russo F, Pitzalis S, Spitoni G, Aprile T, Patria F, Spinelli D et al (2005) Identification of the neural sources of the pattern-reversal VEP. Neuroimage 24(3):874–886
Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM (2001) Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain 124(Pt 9):1813–1820
Sartucci F, Orlandi G, Lucetti C, Bonuccelli U, Murri L, Orsini C et al (2003) Changes in pattern electroretinograms to equiluminant red–green and blue–yellow gratings in patients with early Parkinson’s disease. J Clin Neurophysiol 20(5):375–381
Ungerleider LG, Haxby JV (1994) ‘What’ and ‘where’ in the human brain. Curr Opin Neurobiol 4(2):157–165
Goodale MA, Milner AD (1992) Separate visual pathways for perception and action. Trends Neurosci 15(1):20–25
Chan JW (2012) Recent advances in optic neuritis related to multiple sclerosis. Acta Ophthalmol 90(3):203–209
Petzold A (2016) Optical coherence tomography to assess neurodegeneration in multiple sclerosis. Methods Mol Biol 1304:131–141
Petzold A, de Boer JF, Schippling S, Vermersch P, Kardon R, Green A et al (2010) Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 9(9):921–932
Holder GE (2001) Pattern electroretinography (PERG) and an integrated approach to visual pathway diagnosis. Prog Retin Eye Res. 20(4):531–561
Toosy AT, Mason DF, Miller DH (2014) Optic neuritis. Lancet Neurol 13(1):83–99
Sorensen TL, Frederiksen JL, Bronnum-Hansen H, Petersen HC (1999) Optic neuritis as onset manifestation of multiple sclerosis: a nationwide, long-term survey. Neurology. 53(3):473–478
Engell T, Trojaborg W, Raun NE (1987) Subclinical optic neuropathy in multiple sclerosis. A neuro-ophthalmological investigation by means of visually evoked response, Farnworth-Munsell 100 Hue test and Ishihara test and their diagnostic value. Acta Ophthalmol (Copenh) 65(6):735–740
Brecelj J, Strucl M, Hawlina M (1990) Central fiber contribution to W-shaped visual evoked potentials in patients with optic neuritis. Doc Ophthalmol 75(2):155–163
Rousseff RT, Tzvetanov P, Rousseva MA (2005) The bifid visual evoked potential-normal variant or a sign of demyelination? Clin Neurol Neurosurg 107(2):113–116
Murray TJ (2009) The history of multiple sclerosis: the changing frame of the disease over the centuries. J Neurol Sci 277(Suppl 1):S3–S8
Greenfield J, King L (1936) Observations on the histopathology of the cerebral lesions in disseminated sclerosis. Brain 59(4):445–458
Pulicken M, Gordon-Lipkin E, Balcer LJ, Frohman E, Cutter G, Calabresi PA (2007) Optical coherence tomography and disease subtype in multiple sclerosis. Neurology 69(22):2085–2092
Bock M, Brandt AU, Dorr J, Kraft H, Weinges-Evers N, Gaede G et al (2010) Patterns of retinal nerve fiber layer loss in multiple sclerosis patients with or without optic neuritis and glaucoma patients. Clin Neurol Neurosurg 112(8):647–652
Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120(Pt 3):393–399
Peterson J, Kidd D, Trapp B (2005) Axonal degeneration in multiple sclerosis: the histopathological evidence. In: Waxman S (ed) Multiple sclerosis as a neuronal disease. Elsevier, Amsterdam, pp 165–184
Compston A (2004) Mechanisms of axon-glial injury of the optic nerve. Eye (Lond) 18(11):1182–1187
Cavanagh JB (1964) The significance of the “dying back” process in experimental and human neurological disease. Int Rev Exp Pathol 3:219–267
Graham EC, You Y, Yiannikas C, Garrick R, Parratt J, Barnett MH et al (2016) Progressive loss of retinal ganglion cells and axons in nonoptic neuritis eyes in multiple sclerosis: a longitudinal optical coherence tomography study. Invest Ophthalmol Vis Sci 57(4):2311–2317
Sriram P, Graham SL, Wang C, Yiannikas C, Garrick R, Klistorner A (2012) Transsynaptic retinal degeneration in optic neuropathies: optical coherence tomography study. Invest Ophthalmol Vis Sci 53(3):1271–1275
Celesia GG, Kaufman D, Cone SB (1986) Simultaneous recording of pattern electroretinography and visual evoked potentials in multiple sclerosis. A method to separate demyelination from axonal damage to the optic nerve. Arch Neurol 43(12):1247–1252
Stefano E, Cupini LM, Rizzo P, Pierelli F, Rizzo PA (1991) Simultaneous recording of pattern electroretinogram (PERG) and visual evoked potential (VEP) in multiple sclerosis. Acta Neurol Belg 91(1):20–28
Smith KJ (2006) Axonal protection in multiple sclerosis—A particular need during remyelination? Brain 129(Pt 12):3147–3149
Keough MB, Yong VW (2013) Remyelination therapy for multiple sclerosis. Neurotherapeutics 10(1):44–54